This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)

Tipranks - Tipranks - Sat Jun 6, 12:28PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX).

Claim 55% Off TipRanks

United Therapeutics (UTHR)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on United Therapeutics yesterday and set a price target of $516.00. The company’s shares closed last Friday at $547.17.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.9% and a 57.6% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Vertex Pharmaceuticals, and Intellia Therapeutics. ;'>

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $665.90.

See the top stocks recommended by analysts >>

Fate Therapeutics (FATE)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Fate Therapeutics, with a price target of $6.00. The company’s shares closed last Friday at $2.01.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 3.6% and a 40.2% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals. ;'>

Fate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.78, implying a 122.3% upside from current levels. In a report issued on May 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

Edgewise Therapeutics (EWTX)

J.P. Morgan analyst Tessa Romero assigned a Buy rating to Edgewise Therapeutics today and set a price target of $53.00. The company’s shares closed last Friday at $35.53, close to its 52-week high of $38.12.

According to TipRanks.com, Romero is a 4-star analyst with an average return of 15.9% and a 50.0% success rate. Romero covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., EyePoint Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edgewise Therapeutics with a $46.89 average price target, a 25.8% upside from current levels. In a report issued on June 2, TipRanks – Google also upgraded the stock to Buy with a $38.00 price target.

Read More on UTHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).